Trial Profile
A Phase 1b Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Aug 2023
Price :
$35
*
At a glance
- Drugs Aglatimagene besadenovec (Primary) ; Valaciclovir
- Indications Glioma
- Focus Adverse reactions
- Sponsors Advantagene; Candel Therapeutics
- 10 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 20 Nov 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 24 Feb 2012 Planned End Date changed from 1 Dec 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.